Comparison of Coronary Artery Bypass Grafting and Drug-Eluting Stents in Patients with Left Main Coronary Artery Disease and Chronic Kidney Disease: A Systematic Review and Meta-Analysis.


Journal

Cardiovascular revascularization medicine : including molecular interventions
ISSN: 1878-0938
Titre abrégé: Cardiovasc Revasc Med
Pays: United States
ID NLM: 101238551

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 24 12 2018
revised: 14 01 2019
accepted: 14 01 2019
pubmed: 8 3 2019
medline: 28 7 2020
entrez: 8 3 2019
Statut: ppublish

Résumé

Treatment of left main coronary artery disease (LMCAD) in patients with chronic kidney disease (CKD) with either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) remains controversial. Therefore, we performed a meta-analysis to evaluate the optimal choice of therapy when treating LMCAD in patients with CKD. We performed an electronic database search of Pubmed, Embase, and Cochrane Library for all studies that compared PCI with CABG when treating LMCAD in the setting of CKD. Major adverse cardiac and cerebrovascular events (MACCE) were the primary outcome. Secondary outcomes included myocardial infarction (MI), cerebrovascular events, all-cause mortality, and repeat revascularization. Our analysis included 5 studies (2 randomized controlled trial and 3 retrospective) representing a total of 1212 patients. Mean follow up was 3.4 ± 1.3 years. Our study demonstrated a significant reduction in MACCE for patients treated with CABG compared with PCI (odd ratio [OR] 0.72; 95% confidence interval [CI] 0.55-0.95, P = 0.02, I In patients with CKD requiring LMCAD intervention, CABG is associated with a lower risk of MACCE, MI, and repeat revascularization, however it was associated with an increased risk of cerebrovascular accidents when compared to patients who received PCI therapy. Further RCTs with sufficient power are required to confirm these findings.

Sections du résumé

BACKGROUND BACKGROUND
Treatment of left main coronary artery disease (LMCAD) in patients with chronic kidney disease (CKD) with either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) remains controversial. Therefore, we performed a meta-analysis to evaluate the optimal choice of therapy when treating LMCAD in patients with CKD.
METHOD METHODS
We performed an electronic database search of Pubmed, Embase, and Cochrane Library for all studies that compared PCI with CABG when treating LMCAD in the setting of CKD. Major adverse cardiac and cerebrovascular events (MACCE) were the primary outcome. Secondary outcomes included myocardial infarction (MI), cerebrovascular events, all-cause mortality, and repeat revascularization.
RESULTS RESULTS
Our analysis included 5 studies (2 randomized controlled trial and 3 retrospective) representing a total of 1212 patients. Mean follow up was 3.4 ± 1.3 years. Our study demonstrated a significant reduction in MACCE for patients treated with CABG compared with PCI (odd ratio [OR] 0.72; 95% confidence interval [CI] 0.55-0.95, P = 0.02, I
CONCLUSION CONCLUSIONS
In patients with CKD requiring LMCAD intervention, CABG is associated with a lower risk of MACCE, MI, and repeat revascularization, however it was associated with an increased risk of cerebrovascular accidents when compared to patients who received PCI therapy. Further RCTs with sufficient power are required to confirm these findings.

Identifiants

pubmed: 30842042
pii: S1553-8389(19)30050-8
doi: 10.1016/j.carrev.2019.01.018
pii:
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1184-1189

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Mahmoud Barbarawi (M)

Department of Internal Medicine, Hurley Medical Center/Michigan State University, Flint, MI 48503, USA.

Yazan Zayed (Y)

Department of Internal Medicine, Hurley Medical Center/Michigan State University, Flint, MI 48503, USA.

Kewan Hamid (K)

Department of Internal Medicine, Hurley Medical Center/Michigan State University, Flint, MI 48503, USA.

Babikir Kheiri (B)

Department of Internal Medicine, Hurley Medical Center/Michigan State University, Flint, MI 48503, USA.

Owais Barbarawi (O)

Department of Internal Medicine, Mutah University, Al-Karak, Jordan.

Saira Sundus (S)

Department of Internal Medicine, Hurley Medical Center/Michigan State University, Flint, MI 48503, USA.

Laith Rashdan (L)

Department of Internal Medicine, Hurley Medical Center/Michigan State University, Flint, MI 48503, USA.

Ahmad Alabdouh (A)

Department of Internal Medicine, Saint Agnes Hospital, Baltimore, MD 21229, USA.

Adam Chahine (A)

Department of Internal Medicine, Hurley Medical Center/Michigan State University, Flint, MI 48503, USA.

Ghassan Bachuwa (G)

Department of Internal Medicine, Hurley Medical Center/Michigan State University, Flint, MI 48503, USA.

Mohammad Luay Alkotob (ML)

Division of Cardiology, Hurley Medical Center/Michigan State University, Flint, MI 48503, USA. Electronic address: luaymd@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH